Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TENEO: Docetaxel and Cetuximab in Triple Negative Breast Cancer
NCT00600249Phase 2Completed
- Sponsor
- Centre Jean Perrin
- Start
- Jan 2008
- Primary completion
- May 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in triple negative breast cancer (TNBC), sponsored by Centre Jean Perrin. Started Jan 2008; status: completed.
02
Drugs
cetuximab
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT00600249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00600249.